Sphingosine kinases as druggable targets

Susan Pyne; David R. Adams; Nigel J. Pyne

doi:10.1007/164_2018_96

Sphingosine kinases as druggable targets

Susan Pyne, David R. Adams, Nigel J. Pyne

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

12 Citations (Scopus)

77 Downloads (Pure)

Abstract

There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid, sphingosine 1-phosphate are involved in physiological and pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.

Original language	English
Title of host publication	Lipid Signaling in Human Diseases
Subtitle of host publication	Handbook of Experimental Pharmacology
Editors	Julian Gomez-Cambronero, Michael A. Frohman
Place of Publication	Cham, Switzerland
Chapter	10
Pages	49-76
Number of pages	28
Volume	259
ISBN (Electronic)	978-3-030-33668-4
DOIs	https://doi.org/10.1007/164_2018_96
Publication status	Published - 25 Apr 2020

Keywords

Sphingosine kinase
sphingosine 1-phosphate (SIP)
cancer
pulmonary hypertension
Inflammation
neurodegeneration
sickling

Access to Document

10.1007/164_2018_96

Pyne-etal-Springer-Sphingosine-kinases-as-druggableAccepted author manuscript, 0.99 MB

Cite this

@inbook{449c78f786f4458693ea8b5121a7407d,

title = "Sphingosine kinases as druggable targets",

abstract = "There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid, sphingosine 1-phosphate are involved in physiological and pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.",

keywords = "Sphingosine kinase, sphingosine 1-phosphate (SIP), cancer, pulmonary hypertension, Inflammation, neurodegeneration, sickling",

author = "Susan Pyne and Adams, {David R.} and Pyne, {Nigel J.}",

year = "2020",

month = apr,

day = "25",

doi = "10.1007/164_2018_96",

language = "English",

isbn = "978-3-030-33667-7",

volume = "259",

pages = "49--76",

editor = "Julian Gomez-Cambronero and Frohman, {Michael A.}",

booktitle = "Lipid Signaling in Human Diseases",

}

TY - CHAP

T1 - Sphingosine kinases as druggable targets

AU - Pyne, Susan

AU - Adams, David R.

AU - Pyne, Nigel J.

PY - 2020/4/25

Y1 - 2020/4/25

N2 - There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid, sphingosine 1-phosphate are involved in physiological and pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.

AB - There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid, sphingosine 1-phosphate are involved in physiological and pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.

KW - Sphingosine kinase

KW - sphingosine 1-phosphate (SIP)

KW - cancer

KW - pulmonary hypertension

KW - Inflammation

KW - neurodegeneration

KW - sickling

U2 - 10.1007/164_2018_96

DO - 10.1007/164_2018_96

M3 - Chapter

SN - 978-3-030-33667-7

VL - 259

SP - 49

EP - 76

BT - Lipid Signaling in Human Diseases

A2 - Gomez-Cambronero, Julian

A2 - Frohman, Michael A.

CY - Cham, Switzerland

ER -

Sphingosine kinases as druggable targets

Abstract

Keywords

Access to Document

Fingerprint

Cite this